Autopsy report · NCT06527404
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Ran for about 1 year 11 months before it stopped.
- 469 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Amgen
- Sponsor type
- Industry
- Conditions
- Prurigo Nodularis
- Interventions
- Rocatinlimab; Placebo
- Participants
- 469
- Sites
- 192
- Countries
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Finland, France, Germany, Greece and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.